Related Experiment Videos
[Calcimimetics--a new treatment for hyperparathyroidism?].
Grzegorz Piecha1, Jerzy Chudek, Andrzej Wiecek
1Klinika Nefrologii, Endokrynologii i Chorób Przemiany Materii Slaskiej Akademii Medycznej w Katowicach.
Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|September 16, 2005
Summary
Calcimimetics, drugs targeting the calcium-sensing receptor (CaR), effectively reduce excess parathormone (PTH) secretion in hyperparathyroidism. Clinical trials show AMG 073 significantly lowers PTH and phosphorus levels with minimal side effects.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Primary and secondary hyperparathyroidism share excess parathormone (PTH) secretion.
- The calcium-sensing receptor (CaR) is crucial for regulating PTH secretion.
- CaR gene mutations alter PTH set-points, leading to hypercalcemia or hypocalcemia.
Purpose of the Study:
- To evaluate calcimimetics as a novel therapeutic class for hyperparathyroidism.
- To assess the efficacy and safety of calcimimetics in managing PTH levels.
Main Methods:
- Review of first-generation calcimimetics (NPS R-467, NPS R-568) in animal models and short-term human trials.
- Analysis of clinical trial data for second-generation calcimimetic AMG 073 in hyperparathyroidism patients.
Main Results:
- Calcimimetics demonstrated effectiveness in suppressing PTH secretion.
- AMG 073 significantly decreased serum PTH and phosphorus levels.
- AMG 073 showed a low incidence of hypocalcemia and other side effects.
Conclusions:
- Calcimimetics represent a promising new therapeutic option for hyperparathyroidism.
- They may offer an alternative to vitamin D analogs or surgical interventions.
- Further research supports calcimimetics as a potential treatment for PTH regulation disorders.